NASDAQ: KRON
Kronos Bio Inc Stock Forecast, Predictions & Price Target

Analyst price target for KRON

Based on 1 analyst offering 12 month price targets for Kronos Bio Inc

Min Forecast
$1.00+14.16%
Avg Forecast
$1.00+14.16%
Max Forecast
$1.00+14.16%

Should I buy or sell KRON stock?

Based on 1 analyst offering ratings for Kronos Bio Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their KRON stock forecasts and price targets.

KRON stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-11-14

1 of 1

Forecast return on equity

Is KRON forecast to generate an efficient return?

Company
N/A
Industry
79.92%
Market
61.93%

Forecast return on assets

Is KRON forecast to generate an efficient return on assets?

Company
N/A
Industry
22.66%

KRON earnings per share forecast

What is KRON's earnings per share in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.26

KRON revenue forecast

What is KRON's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$4.0M-59.38%

KRON vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KRON$0.88$1.00+14.16%Hold
PEPG$1.62$10.33+537.84%Hold
PDSB$1.15$10.00+769.57%Strong Buy
SER$5.50$11.00+100.00%Strong Buy
BYSI$1.36N/AN/A

Kronos Bio Stock Forecast FAQ

Is Kronos Bio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: KRON) stock is to Hold KRON stock.

Out of 1 analyst, 0 (0%) are recommending KRON as a Strong Buy, 0 (0%) are recommending KRON as a Buy, 1 (100%) are recommending KRON as a Hold, 0 (0%) are recommending KRON as a Sell, and 0 (0%) are recommending KRON as a Strong Sell.

If you're new to stock investing, here's how to buy Kronos Bio stock.

What is KRON's earnings growth forecast for 2025-2025?

(NASDAQ: KRON) Kronos Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.82%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.6%.

Kronos Bio's earnings in 2025 is -$86,079,000.

In 2025, KRON is forecast to generate -$76,821,210 in earnings, with the lowest earnings forecast at -$76,821,210 and the highest earnings forecast at -$76,821,210.

What is KRON's revenue growth forecast for 2025-2025?

(NASDAQ: KRON) Kronos Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 148.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.62%.

Kronos Bio's revenue in 2025 is $9,848,000.

In 2025, KRON is forecast to generate $243,876,856 in revenue, with the lowest revenue forecast at $243,876,856 and the highest revenue forecast at $243,876,856.

What is KRON's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: KRON) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 22.66%.

What is KRON's Price Target?

According to 1 Wall Street analyst that have issued a 1 year KRON price target, the average KRON price target is $1.00, with the highest KRON stock price forecast at $1.00 and the lowest KRON stock price forecast at $1.00.

The Wall Street analyst predicted that Kronos Bio's share price could reach $1.00 by Nov 14, 2025. The average Kronos Bio stock price prediction forecasts a potential upside of 14.16% from the current KRON share price of $0.88.

What is KRON's Earnings Per Share (EPS) forecast for 2025-2025?

(NASDAQ: KRON) Kronos Bio's current Earnings Per Share (EPS) is -$1.43. In 2025, KRON's EPS is forecast to hit -$1.26 (min: -$1.26, max: -$1.26).

What is KRON's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: KRON) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.